Revolo Biotherapeutics to Present at May Medical Meetings

Revolo Biotherapeutics, based in Gaithersburg, Maryland, and Cambridge, United Kingdom, is set to showcase its advancements in immune system therapies at two upcoming medical conferences. The company, which focuses on developing treatments for autoimmune and allergic diseases, aims to achieve remission without the immune suppression typical of current therapies. Revolo will present at the American Thoracic Society (ATS) 2024 International Conference and the 6th Treg Directed Therapies Summit in May.

At the ATS 2024 conference, which runs from May 17-22 in San Diego, Revolo will feature a poster presentation titled "IRL201104, A Novel Immunomodulatory Peptide, Shows Efficacy on Inflammatory Endpoints and Airway Hyperresponsiveness in a House Dust Mite Driven Model of Allergic Inflammation with or Without Poly I:C Exacerbation." This presentation, numbered 804 in the D21 session, will be discussed on May 22 from 8:15 to 10:15 a.m. PT in Room 31A-C of the San Diego Convention Center. Jorge De Alba, the company's Vice President of Discovery and Translational Science, will present the findings.

Following this, Revolo will participate in the 6th Treg Directed Therapies Summit from May 21-23 in Boston. Here, Chief Scientific Officer Roly Foulkes will deliver an oral presentation on May 22 from 12:00 to 12:30 p.m. ET. The presentation, part of the session on Non-Cell Based Approaches, is titled "'1104, an immune-resetting peptide, for the treatment of allergic disease," and will explore the use of ‘1104 in inducing T regulatory (Treg) cells in vivo.

Revolo Biotherapeutics is committed to developing innovative therapies that reset the immune system to a balanced state, potentially offering remission for patients suffering from autoimmune and allergic conditions. The company’s two primary drug candidates, ‘1805 and ‘1104, are designed to shift the immune system from a pro-inflammatory state to a regulated one by stimulating T regulatory and B regulatory cells with just a single dose.

‘1104, a pioneering peptide, has undergone evaluation in two Phase 2a clinical trials. These trials involved patients with eosinophilic esophagitis (EoE) and those with allergen sensitivities. Revolo is now progressing ‘1104 into a Phase 2b trial for EoE, along with a Phase 2a trial for atopic dermatitis or asthma, while exploring its potential for treating other allergic conditions.

The second drug candidate, ‘1805, is a modified version of a key protein involved in immune function. Revolo plans to assess ‘1805 in a Phase 2 clinical trial for patients with moderate-to-severe rheumatoid arthritis and a Phase 2a trial for ulcerative colitis. The mechanisms of these drug candidates are not specific to any single disease, providing a versatile platform for developing treatments for various autoimmune and allergic diseases.

Revolo Biotherapeutics’ approach offers a promising alternative to current treatments, aiming to achieve sustained remission without the adverse effects of immune suppression. This innovative strategy is underpinned by the induction of regulatory cells that maintain immune homeostasis, potentially transforming the management of chronic immune disorders.